- Home
- ARQT vs KFY Comparison
ARQT vs KFY Comparison
Compare ARQT & KFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | KFY |
|---|---|---|
| Founded | 2016 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.4B |
| IPO Year | 2020 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ARQT | KFY |
|---|---|---|
| Price | $24.58 | $62.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $31.86 | ★ $78.00 |
| AVG Volume (30 Days) | ★ 1.2M | 503.7K |
| Earning Date | 05-25-2026 | 06-08-2026 |
| Dividend Yield | N/A | ★ 3.02% |
| EPS Growth | ★ 88.79 | 42.41 |
| EPS | N/A | ★ 2.61 |
| Revenue | $376,072,000.00 | ★ $1,819,519,000.00 |
| Revenue This Year | $34.46 | $5.75 |
| Revenue Next Year | $29.77 | $4.02 |
| P/E Ratio | ★ N/A | $24.29 |
| Revenue Growth | ★ 91.34 | 12.20 |
| 52 Week Low | $11.86 | $58.95 |
| 52 Week High | $31.77 | $78.50 |
Technical Indicators
Market Signals| Indicator | ARQT | KFY |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 45.66 |
| Support Level | $22.26 | $58.95 |
| Resistance Level | $27.65 | $63.51 |
| Average True Range (ATR) | 1.54 | 1.90 |
| MACD | -0.18 | 0.30 |
| Stochastic Oscillator | 29.08 | 55.86 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
About KFY Korn Ferry
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.